PTO/SB/06a (05-07)
Approved for use through 09/09/207 OMS 0851-0231
U.S. Patenti and Trademark Office, U.S. DEPARTMENT OF COMMERCE It os collection of information unless it contrars a valid OMS control number. Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	
(Not for submission under 37 CFR 1.99)	
(,	

	Application Number		10737113				
	Filing Date		2003-12-16				
First Named Inventor Rober		Rober	ert E. Brilley				
	Art Unit		1773				
	Examiner Name	Kevin	R, Kruer				
Attorney Docket Number		er	ICTC-66992				

				Attorn	ey Doc	ocket Number ICTC-66992					
					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number Kind Code		Issue Date		Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear			
	1										
If you wis	h to a	dd additional U.S. Pater	nt citatio	n informa	ation pl	lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	ICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Pate of cited Docum	entee or Applicant Relev		s,Columns,Lines where vant Passages or Relevant es Appear		
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add		
If you wis	h to a	dd additional U.S. Publi		,		n information p		d button	Add		
If you wisi		dd additional U.S. Publi Foreign Document Number ³		FOREIC		Publication		e or	Remove Pages,Coll where Rele	or Relevant	т.
Examiner	Cite	Foreign Document	Country	FOREIC	N PAT	Publication	Name of Patente	e or	Remove Pages,Col where Rele Passages	evant or Relevant	١,,
Examiner	Cite No	Foreign Document Number ³	Country Code ²	FOREIC	Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Remove Pages,Col where Rele Passages	evant or Relevant	To
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² EP	FOREIG	Kind Code ⁴ A1	Publication Date 2000-03-15 2000-05-31	Name of Patente Applicant of cited Document McDonnell Dougla	e or	Remove Pages,Col where Rele Passages	evant or Relevant	Т

Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Pattern Documents at year USPTIO_GCDV or MEPE 901.6.2 Eater office that issued the document, by the holiefler code (WIPO Standard ST3.) 3 for duplance platfort documents, by the challenge of the Emperior must proceche the serial number of the period ocuments. It will advance to a compared the properties are not to the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here it English targuages the relation to a standard.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10737113		
Filing Date		2003-12-16		
First Named Inventor Rober		rt E. Briley		
Art Unit		1773		
Examiner Name	Kevin R. Kruer			
Attorney Docket Number		ICTC-66992		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David G. Parkhurst/	Date (YYYY-MM-DD)	2007-08-22
Name/Print	David G Parkhurst	Registration Number	29.422

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. O. 8bx 1450, Alexandria, V.S. 2313-1450. D. ORY SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.